Closing the gap: Novel therapies in treating acute lymphoblastic leukemia in adolescents and young adults
- 1 March 2018
- journal article
- review article
- Published by Elsevier in Blood Reviews
- Vol. 32 (2) , 122-129
Abstract
No abstract availableKeywords
This publication has 83 references indexed in Scilit:
- Tyrosine Kinase Inhibitor Therapy Induces Remission in a Patient With Refractory EBF1-PDGFRB–Positive Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2013
- CTLA-4 Blockade following Relapse of Malignancy after Allogeneic Stem Cell Transplantation Is Associated with T Cell Activation But Not with Increased Levels of T Regulatory CellsTransplantation and Cellular Therapy, 2011
- Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An UpdateJournal of Clinical Oncology, 2011
- PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cellsBlood, 2011
- Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2010
- Outcomes for Children and Adolescents With Cancer: Challenges for the Twenty-First CenturyJournal of Clinical Oncology, 2010
- Trends in 5- and 10-year Survival After Diagnosis with Childhood Hematologic Malignancies in the United States, 1990–2004JNCI: Journal of the National Cancer Institute, 2008
- What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studiesBlood, 2008
- The Teenage Cancer Trust—advocating a model for teenage cancer servicesEuropean Journal of Cancer, 2003
- CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cellsBlood, 2002